Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Identification of Novel Therapies for High Risk Metastatic Neuroblastoma

FY 2015-16

Summary
Neuroblastoma (NB) is the most common pediatric cancer and the leading cause of childhood cancer mortality. Despite intensive treatment, the overall survival for patients with high risk metastatic NB is less than 10%. Furthermore, there are currently no mouse or cell models that are able to faithfully recapitulate metastatic NB. As a response to this issue, our lab has established novel strategies and models to improve metastatic NB research. Using these models, we have screened and validated potential drugs that have shown promising effects for NB growth inhibition. These preliminary results have highlighted the effectiveness of our high throughput screens and NB models, as well as our ability to identify novel combinations for high risk NB. In this research project, we will continue to use these models as platforms for novel candidate drug discovery, as well as to determine their efficacy, mechanisms of action, and clinical potential. We predict that these strategies will more accurately identify novel therapeutic agents that specifically and effectively target metastatic NB, the most common cause of death among NB patients.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
339750
Name
Valencia Sama Ivette
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Identification of Novel Therapies for High Risk Metastatic Neuroblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cell Viability Assays; Clinical Applications; Drug Discovery; High Risk Metastatic Neuroblastoma; In Vivo Models; Metastasis; Migration And Invasion Assays; Neuroblastoma; Pediatric Cancer; Targeted Therapy
Abstract
Neuroblastoma (NB) is the most common pediatric cancer and the leading cause of childhood cancer mortality. Despite intensive treatment, the overall survival for patients with high risk metastatic NB is less than 10%. Furthermore, there are currently no mouse or cell models that are able to faithfully recapitulate metastatic NB. As a response to this issue, our lab has established novel strategies and models to improve metastatic NB research. Using these models, we have screened and validated potential drugs that have shown promising effects for NB growth inhibition. These preliminary results have highlighted the effectiveness of our high throughput screens and NB models, as well as our ability to identify novel combinations for high risk NB. In this research project, we will continue to use these models as platforms for novel candidate drug discovery, as well as to determine their efficacy, mechanisms of action, and clinical potential. We predict that these strategies will more accurately identify novel therapeutic agents that specifically and effectively target metastatic NB, the most common cause of death among NB patients.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Valencia Sama, Ivette
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2015-16) | Canada Spends